The latest from CDMOs, CMOs, and suppliers featuring PharmaLogic, Phillips Medisize and Charles River Laboratories.  

Chemicals/Chemical API Manufacturing 
* PharmaLogic To Acquire Lantheus’ Radiopharma CDMO Business
* Philips Medisize Acquires Facility for Inhalation Center of Excellence
General 
* Charles River To Acquire Frontage’s Bioanalysis & DMPK Business

---

Chemicals/Chemical API Manufacturing 

PharmaLogic To Acquire Lantheus’ Radiopharma CDMO Business 
PharmaLogic Holdings, a CDMO of radiopharmaceuticals for both therapeutics and diagnostics, has agreed to acquire the CDMO business and Springfield, New Jersey, manufacturing facility of Lantheus Holdings, a North Billerica, Massachusetts-based bio/pharmaceutical company focused on radiopharmaceuticals. 

The Springfield facility produces both radiopharmaceuticals and theranostics for research and clinical development. The acquisition will add to the capabilities of Agilera, PharmaLogic’s therapeutic CDMO business, upon completion of the transaction. The transaction also includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus. Lantheus received FDA approval in September (September 2026) for its abbreviated new drug application for Bravnetsa (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to the reference product, Novartis’ Lutathera (lutetium Lu 177 dotatate). Bravnetsa is indicated for treating adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.

The transaction is subject to applicable regulatory review and the satisfaction of other customary closing conditions. The parties will continue to operate independently until the closing. 

Source: PharmaLogic  

---

Philips Medisize Acquires Facility for Inhalation Center of Excellence 
Phillips Medisize, a CDMO specializing in the design, development, and manufacturing of drug-delivery systems, medical devices, and in vitro diagnostic products, has announced an investment to acquire the complete footprint of its site in Chippenham, UK site, which serves as an Innovation and Development Center. The Chippenham, UK, site, along with its Innovation and Development Center, in Cambridge, UK, serves as the company’s Inhalation Center of Excellence.  

The Chippenham footprint of 58,963 square meters (634,670 square feet) on approximately 3.41 acres provides Phillips Medisize with long-term operational control to broaden drug–device combination product formulation development for both early- and late-phase clinical trial supplies manufacturing. This acquisition supports an anticipated growing pipeline of complex inhaled small-molecule and biologic therapies.  

Source: Phillips Medisize 

---

General 

Charles River To Acquire Frontage’s Bioanalysis & DMPK Business 
Charles River Laboratories has agreed to acquire the bioanalysis and drug metabolism and pharmacokinetics (DMPK) operations in Exton, Pennsylvania, of Frontage Holdings, a contract research, development, and manufacturing organization, in a deal worth up to $545 million ($470 million upfront and $75 million in milestone payments). The deal is part of a larger proposed asset restructuring of Frontage Holdings, which is being divided among an investor consortium, comprising Charles River Laboratories, Tigermed, a CRO, and Dr. Song Li, Frontage’s Chairman. 

Frontage’s laboratory testing sites that are being acquired by Charles River Laboratories provide a suite of bioanalysis, biomarker, and DMPK testing services for large and small molecules, primarily supporting clinical development program. The planned acquisition includes a CLIA-certified central laboratory and encompasses two sites in Exton, Pennsylvania that operate across approximately 150,000 square feet and employ approximately 340 people. 

Under the agreement, Charles River will acquire the bioanalysis and DMPK business for approximately $470 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes additional payments of up to $75 million, contingent on future performance of the acquired businesses. The transaction is expected to close during the first half of 2027, subject to required shareholder and regulatory approvals, and other customary closing conditions. 

Source: Charles River Laboratories